ArticleScientific reports2026
AZD6738 overcomes acquired olaparib resistance in BRCA1 mutation triple-negative breast cancer through down-regulation of BRCA2 and RAD51.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Although olaparib, a PARP inhibitor, has been approved for the treatment with triple-negative breast cancer (TNBC) harboring BRCA1/2 mutations, resistance inevitably emerges in TNBC patients. Ataxia telangiectasia and Rad3-related (ATR) protein play a role in the chemotherapy and radiotherapy of various malignancies. However, the role of ATR in olaparib resistance to TNBC remains unclear. This study aimed to explore the synergistic cytotoxic effects of dual inhibition of ATR and PARP in olaparib-resistant TNBC cell lines and to elucidate the underlying molecular mechanism. Herein, olaparib-resistant and parental HCC1937 and MDA-MB-436 cell lines were treated with the ATR inhibitor AZD6738 and the PARP inhibitor olaparib at various concentrations. Cell viability was assessed using MTT. DNA damage was evaluated by alkaline comet assay, while apoptosis and cell cycle were analyzed using flow cytometry. The expression levels of BRCA2, RAD51, and γH2AX were examined via immunofluorescence, western blot, and immunohistochemistry analysis. Additionally, an olaparib-resistant HCC1937 xenograft model was employed to evaluate the in vivo antitumor efficacy of AZD6738, olaparib, either alone or in combination. Our results demonstrate that AZD6738 and olaparib exerted synergistic cytotoxic effects in olaparib-resistant TNBC cell lines by accelerating cell cycle progression, inducing DNA damage and apoptosis. Furthermore, in vivo experiments revealed that the combination of olaparib and AZD6738 significantly inhibited the growth of olaparib-resistant HCC1937 xenografts compared with the monotherapy groups, while also promoting increased γH2AX expression without inducing significant body weight loss. Importantly, AZD6738 and olaparib significantly downregulated the protein expression of BRCA2, and RAD51, thereby reversing olaparib-induced activation of the DNA homologous recombination (HR) repair signaling pathways. In conclusion, dual inhibition of ATR and PARP represents a highly promising therapeutic strategy for TNBC with acquired resistance to olaparib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.